Skip to main content
Top
Published in: Endocrine Pathology 2/2021

01-06-2021 | Pituitary Adenoma

Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors

Author: Sylvia L. Asa

Published in: Endocrine Pathology | Issue 2/2021

Login to get access

Abstract

Detailed analysis of cytodifferentiation and hormone production has classified pituitary neuroendocrine tumors (PitNETs) in a formal system that reflects the lineage differentiation of nontumorous adenohypophysial cells as well as subtypes of tumors that have predictive value. In addition, tumors composed of cells that lack terminal differentiation are well characterized. To comply with the proposal to create an overarching classification of neuroendocrine neoplasia, these tumors are now called PitNETs rather than adenomas. The next important step will be to relinquish the term “pituitary carcinoma” for metastatic PitNETs that remain well differentiated, and to alter the terminology used for tumors that are not terminally differentiated to reflect only their immature lineage. The existence of mixed neuroendocrine and non-neuroendocrine neoplasms (MiNENs) similar to those at other body sites is proven by mixed craniopharyngiomas with PitNETs. As with other NETs, these neoplasms should be reported with synoptic data that guide completeness of reporting. A formal system of grading should be created, but not only based on proliferation, as these tumors have shown the prognostic value of cytodifferentiation. A formal system of staging should also be devised to complement grade in the thorough and accurate diagnosis of tumors that arise from adenohypophysial cells.
Literature
1.
go back to reference Asa SL, Perry A. Tumors of the Pituitary Gland. AFIP Atlas of Tumor and Nontumor Pathology, Series 5, Fascicle 1. Arlington VA: ARP Press; 2020. Asa SL, Perry A. Tumors of the Pituitary Gland. AFIP Atlas of Tumor and Nontumor Pathology, Series 5, Fascicle 1. Arlington VA: ARP Press; 2020.
2.
go back to reference Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770-86.PubMedPubMedCentralCrossRef Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770-86.PubMedPubMedCentralCrossRef
3.
go back to reference Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017;24:C5-C8.PubMedCrossRef Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017;24:C5-C8.PubMedCrossRef
4.
go back to reference Asa S.L., Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, et al. Pituitary Neuroendocrine Tumors: A Model for Neuroendocrine Tumor Classification. Mod Pathol 2021, in press. Asa S.L., Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, et al. Pituitary Neuroendocrine Tumors: A Model for Neuroendocrine Tumor Classification. Mod Pathol 2021, in press.
5.
go back to reference Asa SL, Mete O, Ezzat S. Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know? Endocr Pathol 2021;32:3-16.PubMedCrossRef Asa SL, Mete O, Ezzat S. Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know? Endocr Pathol 2021;32:3-16.PubMedCrossRef
6.
go back to reference Casar-Borota O, Boldt HB, Engstrom BE, Andersen MS, Baussart B, Bengtsson D, et al. Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations. J Clin Endocrinol Metab 2020. Casar-Borota O, Boldt HB, Engstrom BE, Andersen MS, Baussart B, Bengtsson D, et al. Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations. J Clin Endocrinol Metab 2020.
7.
go back to reference Alshaikh OM, Asa SL, Mete O, Ezzat S. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. Endocr Pathol 2019;30:118-27.PubMedCrossRef Alshaikh OM, Asa SL, Mete O, Ezzat S. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. Endocr Pathol 2019;30:118-27.PubMedCrossRef
8.
go back to reference McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 2018;178:265-76.PubMedCrossRef McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 2018;178:265-76.PubMedCrossRef
9.
go back to reference Lenders N, McCormack A. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). Pituitary 2018;21:217-29.PubMedCrossRef Lenders N, McCormack A. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). Pituitary 2018;21:217-29.PubMedCrossRef
10.
go back to reference Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 2018;178:G1-G24.PubMedCrossRef Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 2018;178:G1-G24.PubMedCrossRef
11.
go back to reference Kawashima ST, Usui T, Sano T, Iogawa H, Hagiwara H, Tamanaha T, et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease. Clin Endocrinol (Oxf) 2009;70:656-7.CrossRef Kawashima ST, Usui T, Sano T, Iogawa H, Hagiwara H, Tamanaha T, et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease. Clin Endocrinol (Oxf) 2009;70:656-7.CrossRef
12.
go back to reference Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV. P53 gene mutations in pituitary carcinomas. Endocr Pathol 2007;18:217-22.PubMedCrossRef Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV. P53 gene mutations in pituitary carcinomas. Endocr Pathol 2007;18:217-22.PubMedCrossRef
13.
go back to reference Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-71.PubMedCrossRef Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-71.PubMedCrossRef
14.
go back to reference Levy A, Hall L, Yeundall WA, Lightman SL. p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol (Oxf) 1994;41:809-14.CrossRef Levy A, Hall L, Yeundall WA, Lightman SL. p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol (Oxf) 1994;41:809-14.CrossRef
15.
go back to reference Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in USP8 wild type Cushing's disease. Neuro Oncol 2019. Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in USP8 wild type Cushing's disease. Neuro Oncol 2019.
16.
go back to reference Finzi G, Cerati M, Marando A, Zoia C, Ferreli F, Tomei G, et al. Mixed pituitary adenoma/craniopharyngioma: clinical, morphological, immunohistochemical and ultrastructural study of a case, review of the literature, and pathogenetic and nosological considerations. Pituitary 2014;17:53-9.PubMedCrossRef Finzi G, Cerati M, Marando A, Zoia C, Ferreli F, Tomei G, et al. Mixed pituitary adenoma/craniopharyngioma: clinical, morphological, immunohistochemical and ultrastructural study of a case, review of the literature, and pathogenetic and nosological considerations. Pituitary 2014;17:53-9.PubMedCrossRef
17.
go back to reference Moshkin O, Scheithauer BW, Syro LV, Velasquez A, Horvath E, Kovacs K. Collision tumors of the sella: craniopharyngioma and silent pituitary adenoma subtype 3: case report. Endocr Pathol 2009;20:50-5.PubMedCrossRef Moshkin O, Scheithauer BW, Syro LV, Velasquez A, Horvath E, Kovacs K. Collision tumors of the sella: craniopharyngioma and silent pituitary adenoma subtype 3: case report. Endocr Pathol 2009;20:50-5.PubMedCrossRef
18.
19.
go back to reference Yoshida A, Sen C, Asa SL, Rosenblum MK. Composite pituitary adenoma and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation. Am J Surg Pathol 2008;32:1736-41.PubMedCrossRef Yoshida A, Sen C, Asa SL, Rosenblum MK. Composite pituitary adenoma and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation. Am J Surg Pathol 2008;32:1736-41.PubMedCrossRef
20.
go back to reference Scully KM, Rosenfeld MG. Pituitary development: regulatory codes in mammalian organogenesis. Science 2002;295:2231-5.PubMedCrossRef Scully KM, Rosenfeld MG. Pituitary development: regulatory codes in mammalian organogenesis. Science 2002;295:2231-5.PubMedCrossRef
21.
go back to reference Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998;19:798-827.PubMed Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998;19:798-827.PubMed
22.
go back to reference Horvath E, Lloyd RV, Kovacs K. Propylthiouracyl-induced hypothyroidism results in reversible transdifferentiation of somatotrophs into thyroidectomy cells. A morphologic study of the rat pituitary including immunoelectron microscopy. Lab Invest 1990;63:511–20. Horvath E, Lloyd RV, Kovacs K. Propylthiouracyl-induced hypothyroidism results in reversible transdifferentiation of somatotrophs into thyroidectomy cells. A morphologic study of the rat pituitary including immunoelectron microscopy. Lab Invest 1990;63:511–20.
23.
go back to reference Gomez-Hernandez K, Ezzat S, Asa SL, Mete O. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. Turk Patoloji Derg 2015;31 Suppl 1:4-17.PubMed Gomez-Hernandez K, Ezzat S, Asa SL, Mete O. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician. Turk Patoloji Derg 2015;31 Suppl 1:4-17.PubMed
24.
go back to reference Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 2016;29:131-42.PubMedCrossRef Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol 2016;29:131-42.PubMedCrossRef
25.
go back to reference Huang C, Ezzat S, Asa SL, Hamilton J. Dopaminergic resistant prolactinomas in the peripubertal population. J Pediatr Endocrinol Metab 2006;19:951-3.PubMedCrossRef Huang C, Ezzat S, Asa SL, Hamilton J. Dopaminergic resistant prolactinomas in the peripubertal population. J Pediatr Endocrinol Metab 2006;19:951-3.PubMedCrossRef
26.
go back to reference Papathomas TG, Gaal J, Corssmit EP, Oudijk L, Korpershoek E, Heimdal K, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 2014;170:1-12.PubMedCrossRef Papathomas TG, Gaal J, Corssmit EP, Oudijk L, Korpershoek E, Heimdal K, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 2014;170:1-12.PubMedCrossRef
27.
go back to reference Kovacs K, Horvath E, Ryan N, Ezrin C. Null cell adenoma of the human pituitary. Virchows Arch [Pathol Anat ] 1980;387:165-74.CrossRef Kovacs K, Horvath E, Ryan N, Ezrin C. Null cell adenoma of the human pituitary. Virchows Arch [Pathol Anat ] 1980;387:165-74.CrossRef
28.
go back to reference Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018;31:900-9.PubMedCrossRef Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018;31:900-9.PubMedCrossRef
29.
go back to reference Mete O, Asa SL. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocr Pathol 2020;31:330-6.PubMedCrossRef Mete O, Asa SL. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocr Pathol 2020;31:330-6.PubMedCrossRef
30.
go back to reference Asa SL, Gerrie BM, Kovacs K, Horvath E, Singer W, Killinger DW, et al. Structure-function correlations of human pituitary gonadotroph adenomas in vitro. Lab Invest 1988;58:403-10.PubMed Asa SL, Gerrie BM, Kovacs K, Horvath E, Singer W, Killinger DW, et al. Structure-function correlations of human pituitary gonadotroph adenomas in vitro. Lab Invest 1988;58:403-10.PubMed
31.
go back to reference Asa SL, Gerrie BM, Singer W, Horvath E, Kovacs K, Smyth HS. Gonadotropin secretion in vitro by human pituitary null cell adenomas and oncocytomas. J Clin Endocrinol Metab 1986;62:1011-9.PubMedCrossRef Asa SL, Gerrie BM, Singer W, Horvath E, Kovacs K, Smyth HS. Gonadotropin secretion in vitro by human pituitary null cell adenomas and oncocytomas. J Clin Endocrinol Metab 1986;62:1011-9.PubMedCrossRef
32.
go back to reference Asa SL, Bamberger A-M, Cao B, Wong M, Parker KL, Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 1996;81:2165-70.PubMed Asa SL, Bamberger A-M, Cao B, Wong M, Parker KL, Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 1996;81:2165-70.PubMed
33.
go back to reference Mete O, Kefeli M, Caliskan S, Asa SL. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mod Pathol 2019;32:484-9.PubMedCrossRef Mete O, Kefeli M, Caliskan S, Asa SL. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mod Pathol 2019;32:484-9.PubMedCrossRef
34.
go back to reference Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol 2015;26:349-55.PubMedCrossRef Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol 2015;26:349-55.PubMedCrossRef
35.
go back to reference Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med 2018;7. Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med 2018;7.
36.
go back to reference Asa SL, Mete O. Cytokeratin profiles in pituitary neuroendocrine tumors. Hum Pathol 2021;107:87-95.PubMedCrossRef Asa SL, Mete O. Cytokeratin profiles in pituitary neuroendocrine tumors. Hum Pathol 2021;107:87-95.PubMedCrossRef
37.
go back to reference Mete O, Lopes MB, Asa SL. Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma. Am J Surg Pathol 2013;37:1694-9.PubMedCrossRef Mete O, Lopes MB, Asa SL. Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma. Am J Surg Pathol 2013;37:1694-9.PubMedCrossRef
38.
go back to reference Asa SL, Ezzat S, Kelly DF, Cohan P, Takasumi Y, Barkhoudarian G, et al. Hypothalamic Vasopressin-producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease. Am J Surg Pathol 2018;42:251-60. Asa SL, Ezzat S, Kelly DF, Cohan P, Takasumi Y, Barkhoudarian G, et al. Hypothalamic Vasopressin-producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease. Am J Surg Pathol 2018;42:251-60.
39.
go back to reference Asa SL. Survival Guide to Endocrine Pathology. Virginia: Innovative Pathology Press; 2020. Asa SL. Survival Guide to Endocrine Pathology. Virginia: Innovative Pathology Press; 2020.
40.
go back to reference Mete O, Alshaikh OM, Cintosun A, Ezzat S, Asa SL. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. Endocr Pathol 2018;29:332-8.PubMedCrossRef Mete O, Alshaikh OM, Cintosun A, Ezzat S, Asa SL. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. Endocr Pathol 2018;29:332-8.PubMedCrossRef
41.
go back to reference Nose V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R, et al. Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 2011;135:640-6.PubMedCrossRef Nose V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R, et al. Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 2011;135:640-6.PubMedCrossRef
42.
go back to reference Asa SL, Ezzat S. Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. Expert Reviews Endocrinology and Metabolism 2016;11:149-62.CrossRef Asa SL, Ezzat S. Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. Expert Reviews Endocrinology and Metabolism 2016;11:149-62.CrossRef
43.
go back to reference Hardy J. Transsphenoidal microsurgery of prolactinomas. In: Black PM, Zervas N, Ridgeway EC, et al., editors. Secretory Tumors of the Pituitary Gland.New York: Raven Press; 1984. p. 73-81. Hardy J. Transsphenoidal microsurgery of prolactinomas. In: Black PM, Zervas N, Ridgeway EC, et al., editors. Secretory Tumors of the Pituitary Gland.New York: Raven Press; 1984. p. 73-81.
44.
go back to reference Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993;33:610-7. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993;33:610-7.
45.
go back to reference Micko AS, Wohrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 2015;122:803-11.CrossRef Micko AS, Wohrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 2015;122:803-11.CrossRef
46.
go back to reference Raverot G, Vasiljevic A, Jouanneau E, Trouillas J. A prognostic clinicopathologic classification of pituitary endocrine tumors. Endocrinol Metab Clin North Am 2015;44:11-8.PubMedCrossRef Raverot G, Vasiljevic A, Jouanneau E, Trouillas J. A prognostic clinicopathologic classification of pituitary endocrine tumors. Endocrinol Metab Clin North Am 2015;44:11-8.PubMedCrossRef
47.
go back to reference Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013;126:123-35.PubMedCrossRef Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013;126:123-35.PubMedCrossRef
Metadata
Title
Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors
Author
Sylvia L. Asa
Publication date
01-06-2021
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2021
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-021-09678-x

Other articles of this Issue 2/2021

Endocrine Pathology 2/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.